Crinetics Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Crinetics Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q3 2024.
  • Crinetics Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$87.8M, a 48.9% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$307M, a 47.8% decline year-over-year.
  • Crinetics Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$223M, a 32.6% decline from 2022.
  • Crinetics Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$168M, a 55.9% decline from 2021.
  • Crinetics Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$108M, a 43.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$307M -$87.8M -$28.8M -48.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$278M -$82.8M -$29.8M -56.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$248M -$73.5M -$25.6M -53.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$223M -$62.7M -$15.1M -31.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$208M -$59M -$15.5M -35.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$192M -$53M -$9.95M -23.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$182M -$48M -$14.2M -41.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$168M -$47.6M -$16.7M -54% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$151M -$43.5M -$15.6M -56.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$136M -$43M -$17M -65% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$119M -$33.8M -$10.9M -47.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$108M -$30.9M -$9.1M -41.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$98.6M -$27.8M -$9.36M -50.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$89.2M -$26.1M -$9.16M -54.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$80.1M -$22.9M -$5.14M -28.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$75M -$21.8M -$6.58M -43.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$68.4M -$18.5M -$3.22M -21.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$65.2M -$16.9M -$3.58M -26.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$61.6M -$17.8M -$7.74M -77% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$53.8M -$15.2M -$5.78M -61.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-30
Q3 2019 -$48M -$15.2M -$7.16M -88.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$40.9M -$13.3M -$7.66M -135% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$33.2M -$10M -$4.52M -81.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$28.7M -$9.43M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-30
Q3 2018 -$8.07M -$5.7M -240% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$5.68M -$4.04M -246% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$5.53M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q3 2017 -$2.37M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$1.64M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.